title: Tubo-ovarian abscess during therapy of chronic hepatitis C with pegylated interferon and ribavirin.
abstract: BACKGROUND
  Serious infections are rare complications of standard treatment in chronic hepatitis C with pegylated interferon alpha (Peg IFN) and ribavirin.
  
  
  METHODS
  We report two cases of life-threatening tubo-ovarian abscess (TOA) in women older than 40 year of age. No casual risk factors of TOA could be identified in them. In one case septic shock and acute renal failure occured. TOA was caused by endogenic bacteria (Porphyromonas asaccharolytica in the first case and Streptococcus intermedius in the latter). Surgical treatment and interruption of IFN therapy was necessary in both cases.
  
  
  CONCLUSIONS
  Serious gynecological infections may have the significant negative influence on chronic hepatitis C therapy outcome. Because of the risk of TOA developing during IFN therapy gynecological care is needed in chronic hepatitis C management.
authors.affiliation: Department of Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland. minglot@interia.pl
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Inglot
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Szymczak
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Fleischer-Stepniewska
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Fleischer
authors.forename: Bogumila
authors.initials: B
authors.lastname: Staszek-Zurowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gladysz
mesh_terms: D018784:Abdominal Abscess / Q000453:epidemiology / Q000382:microbiology* / Q000601:surgery; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009869:Oophoritis / Q000453:epidemiology / Q000382:microbiology* / Q000601:surgery; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D012488:Salpingitis / Q000453:epidemiology / Q000382:microbiology* / Q000601:surgery
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a